1. Home
  2. LEXX vs VATE Comparison

LEXX vs VATE Comparison

Compare LEXX & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • VATE
  • Stock Information
  • Founded
  • LEXX 2004
  • VATE 1994
  • Country
  • LEXX Canada
  • VATE United States
  • Employees
  • LEXX N/A
  • VATE N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • LEXX Health Care
  • VATE Industrials
  • Exchange
  • LEXX Nasdaq
  • VATE Nasdaq
  • Market Cap
  • LEXX 19.6M
  • VATE 70.3M
  • IPO Year
  • LEXX N/A
  • VATE 1996
  • Fundamental
  • Price
  • LEXX $0.82
  • VATE $5.34
  • Analyst Decision
  • LEXX Strong Buy
  • VATE
  • Analyst Count
  • LEXX 1
  • VATE 0
  • Target Price
  • LEXX $5.00
  • VATE N/A
  • AVG Volume (30 Days)
  • LEXX 89.7K
  • VATE 17.6K
  • Earning Date
  • LEXX 07-14-2025
  • VATE 08-06-2025
  • Dividend Yield
  • LEXX N/A
  • VATE N/A
  • EPS Growth
  • LEXX N/A
  • VATE N/A
  • EPS
  • LEXX N/A
  • VATE N/A
  • Revenue
  • LEXX $615,923.00
  • VATE $1,066,100,000.00
  • Revenue This Year
  • LEXX $6.04
  • VATE N/A
  • Revenue Next Year
  • LEXX $8.36
  • VATE N/A
  • P/E Ratio
  • LEXX N/A
  • VATE N/A
  • Revenue Growth
  • LEXX 49.85
  • VATE N/A
  • 52 Week Low
  • LEXX $0.81
  • VATE $3.25
  • 52 Week High
  • LEXX $4.38
  • VATE $13.79
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 32.80
  • VATE 45.53
  • Support Level
  • LEXX $0.86
  • VATE $5.23
  • Resistance Level
  • LEXX $1.05
  • VATE $5.76
  • Average True Range (ATR)
  • LEXX 0.05
  • VATE 0.24
  • MACD
  • LEXX 0.00
  • VATE 0.04
  • Stochastic Oscillator
  • LEXX 0.14
  • VATE 41.67

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.

Share on Social Networks: